Procaps Group SA (PROC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Procaps Group SA (PROC) has a cash flow conversion efficiency ratio of 1.232x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($47.39 Million) by net assets ($38.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Procaps Group SA to measure how many days the company can operate on defensive assets alone.
Procaps Group SA - Cash Flow Conversion Efficiency Trend (2019–2022)
This chart illustrates how Procaps Group SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Procaps Group SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Procaps Group SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Biosolution Co.Ltd
KQ:086820
|
0.001x |
|
Siam Pan Group PCL
BK:SPG
|
0.014x |
|
Aztek Teknoloji Urunleri Ticaret A.S.
IS:AZTEK
|
-0.167x |
|
Adese Gayrimenkul Yatirim AS
IS:ADESE
|
-0.008x |
|
Bank Panin Syariah Tbk
JK:PNBS
|
-0.084x |
|
We & Win Development Co Ltd
TW:2537
|
0.033x |
|
InflaRx N.V
F:IF0
|
-0.113x |
|
Kyung Nong Corporation
KO:002100
|
0.168x |
Annual Cash Flow Conversion Efficiency for Procaps Group SA (2019–2022)
The table below shows the annual cash flow conversion efficiency of Procaps Group SA from 2019 to 2022. For the full company profile with market capitalisation and key ratios, see Procaps Group SA market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $-1.88 Million | $14.11 Million | -7.511x | -672.00% |
| 2021-12-31 | $-38.34 Million | $37.30 Million | -0.973x | -249.39% |
| 2020-12-31 | $-254.68 Million | $70.92 Million | -0.278x | +0.52% |
| 2019-12-31 | $-243.95 Million | $68.29 Million | -0.280x | -- |
About Procaps Group SA
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use… Read more